“We are unwavering in our commitment to bring apitegromab, the world’s first and only muscle-targeted treatment to improve motor function, to children and adults living with SMA,” said David Hallal, chairman and CEO of Scholar Rock (SRRK). “We are grateful to the FDA, Cure SMA, and our colleagues at Novo Nordisk for the positive engagement at our in-person Type A meeting earlier this week. We are encouraged by the discussion and by our shared understanding of the urgency to bring this important treatment to the SMA community as rapidly as possible.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock Holds Constructive FDA Meeting for Apitegromab
- SRRK Upcoming Earnings Report: What to Expect?
- Scholar Rock price target lowered to $49 from $53 at BofA
- Scholar Rock’s Phase 2 Study on Apitegromab: A Potential Game-Changer for SMA Treatment
- Scholar Rock Faces Regulatory Concerns at Catalent Facility